Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells

European Journal of Biochemistry

Volumn 270, Issue 8, 2003, Pages 1689-1698

  Chua, Anita C G ^a   Ingram, Helen A ^a   Raymond, Kenneth N ^b   Baker, Erica ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Iron chelation therapy; Liver cells; Non transferrin bound iron

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; N,N,N TRIS[3 HYDROXY 1 METHYL 2(1H) PYRIDINONE 4 CARBOXAMINOETHYL]AMINE; PYRIDONE DERIVATIVE; TRANSFERRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL FRACTIONATION; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SYNTHESIS; HEPATOMA CELL; IRON CHELATION; IRON KINETICS; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; DEFEROXAMINE; FERRIC COMPOUNDS; HEPATOCYTES; IRON; IRON CHELATING AGENTS; IRON RADIOISOTOPES; KINETICS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MOLECULAR STRUCTURE; PYRIDONES; RATS; RATS, WISTAR; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0037733128     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1033.2003.03525.x     Document Type: Article

References (48)

1. Batey, R.G., Fong, P.L.C., Shamir, S. & Sherlock, S. (1980) A non-transferrin-bound serum iron in idiopathic hemochromatosis. Dig. Dis. Sci. 25, 340-346.
2. Gutteridge, J.M.C., Rowley, D.A., Griffiths, E. & Halliwell, B. (1985) Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic hemochromatosis. Clin. Sci. 68, 463-467.
3. Grootveld, M., Bell, J.D., Halliwell, B., Aruoma, O.I., Bomford, A. & Sadler, P.J. (1989) Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J. Biol. Chem. 264, 4417-4422.
4. Hershko, C., Graham, G., Bates, G. & Rachmilewitz, E.A. (1978) Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br. J. Haematol. 40, 235-263.
5. Graham, G., Bates, G.W., Rachmilewitz, E.A. & Hershko, C. (1979) Nonspecific serum iron in thalassaemia: quantitation and chemical reactivity. Am. J. Hematol. 6, 207-217.
6. Bradley, S.J., Gosriwitana, I., Srichairatanakool, S., Hider, R.C. & Porter, J.B. (1997) Non-transferrin-bound iron induced by myeloablative chemotherapy. Br. J. Haematol. 99, 337-343.
7. Carmine, T.C., Evans, P., Bruchelt, G., Evans, R., Handgretinger, R., Niethammer, D. & Halliwell, B. (1995) Presence of iron catalytic for free radical reactions in patients undergoing chemotherapy: implications for therapeutic management. Cancer Lett. 94, 219-226.
8. Breuer, W., Hershko, C. & Cabantchik, Z.I. (2000) The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus. Sci. 23, 185-192.
9. Sarkar, B. (1970) State of Fe (III) in normal human serum: low molecular weight and protein ligands besides transferrin. Can. J. Biochem. 48, 1339-1350.
10. Baker, E., Baker, S.M. & Morgan, E.H. (1998) Characterisation of non-transferrin-bound iron (ferric citrate) uptake by rat hepatocytes in culture. Biochim. Biophys. Acta 1380, 21-30.
11. Hershko, C. (1994) Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillieres Clin. Haematol. 7, 965-1000.
12. Hider, R.C., Choudhury, R., Rai, B.L., Dehkordi, L.S. & Singh, S. (1996) Design of orally active iron chelators. Acta Haematol. 95, 6-12.
13. Olivieri, N.F., Brittenham, G.M., McLaren, C.E., Templeton, D.M., Cameron, R.G., McClelland, R.A., Burt, A.D. & Fleming, K.A. (1998) Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassaemia major. N. Engl. J. Med. 339, 417-423.
14. Wong, A., Alder, V., Robertson, D., Papadimitriou, J., Maserei, J., Berdoukas, V., Kontoghiorghes, G., Taylor, E. & Baker, E. (1997) Liver iron depletion and toxicity of the iron chelator Deferiprone (L1, CP20) in the guinea pig. Biometals 10, 247-256.
15. Huebers, H., Huebers, E., Rummel, W. & Crichton, R.R. (1976) Isolation and characterization of iron-binding proteins from rat intestinal mucosa. Eur. J. Biochem. 66, 447-455.
16. Baker, E., Page, M. & Morgan, E.H. (1985) Transferrin and iron release from rat hepatocytes in culture. Am. J. Physiol. 248, G93-G97.
17. Richardson, D.R. & Baker, E. (1992) Two mechanisms of iron uptake from transferrin by melanoma cells: The effect of desferrioxamine and ferric ammonium citrate. J. Biol. Chem. 267, 13972-13979.
18. Hinegardner, R.T. (1971) An improved fluorometric assay for DNA. Anal. Biochem. 39, 197-201.
19. Yeoh, G.C.T., Bennett, F.A. & Oliver, I.T. (1979) Hepatocte differentiation in culture. Appearance of tyrosine aminotransferase. Biochem. J. 180, 153-160.
20. Bacon, B.R., Tavill, A.S., Brittenham, G.M., Park, C.H. & Recknagel, R.O. (1983) Hepatic lipid peroxidation in vivo in rats with chronic iron overload. J. Clin. Invest. 71, 429-439.
21. Nakamura, T., Mori, M. & Awai, M. (1988) Process of carbonyl iron absorption from the rat duodenal mucosa. Acta Physiol. Jpn. 38, 1377-1390.
22. Hirsh, M., Konijn, A.M. & Iancu, T.C. (2002) Acquisition, storage and release of iron by cultured hepatoma cells. J. Hepatol. 36, 30-38.
23. Baker, E., Trinder, D., Torrance, J., Page, M. & Morgan, E.H. (1988) Characteristics of iron exchange between transferrin and hepatocytes in culture. In Thalassaemia, Pathophysiology and Management (Fucharoen, S., Rawley, P.T. & Paul, N.W., eds), pp. 41-61. Alan R. Liss, New York, USA.
24. Trinder, D., Batey, R., Morgan, E.H. & Baker, E. (1990) Effect of cellular iron concentration on iron uptake by hepatocytes. Am. J. Physiol. 259, G611-G617.
25. Baker, E., Richardson, D.R., Gross, S. & Ponka, P. (1992) Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatol. 15, 492-501.
26. Graham, R.M., Morgan, E.H. & Baker, E. (1998) Characterisation of citrate and iron citrate uptake by cultured rat hepatocytes. J. Hepatol. 29, 603-613.
27. Trinder, D. & Morgan, E.H. (1997) Inhibition of uptake of transferrin-bound iron by hepatoma cells by non-transferrin bound iron. Hepatol. 26, 691-698.
28. O'Sullivan, B., Xu, J. & Raymond, K.N. (2000) New multidentate chelators for iron. In Iron Chelators: New Development Strategies, pp. 177-208. Saratoga Publishing Group, Ponte Vedra, Florida, USA.
29. Yokel, R.A., Fredenburg, A.M., Durbin, P.W., Xu, J., Rayens, M.K. & Raymond, K.N. (2000) The hydroxypyridononate Tren-(Me-3,2-HOPO) is a more orally active iron chelator than its bidentate analaogue. J. Pharm. Sci. 89, 545-555.
30. Richardson, D.R., Ponka, P. & Baker, E. (1994) The effect of the iron (III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res. 54, 685-689.
31. Pippard, M.J., Johnson, D.K. & Finch, C.A. Hepatocytes iron kinetics in the rat explored with an iron chelator. Br. J. Haematol. 52, 221-224.
32. Morgan, E.H. & Baker, E. (1986) Iron uptake and metabolism by hepatocytes. Fed. Proc. 45, 2801-2816.
33. Parkes, J.G., Hussain, R.A., Olivieri, N.F. & Templeton, D.M. (1993) Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells. J. Laboratory Clin. Med. 122, 36-47.
34. Parkes, J.G., Randell, E.W., Olivieri, N.F. & Templeton, D.M. (1995) Modulation of iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells. Biochim. Biophys. Acta 1243, 373-380.
35. 3+ transport by iron-loaded cardiac myocytes. Toxicol. 117, 141-151.
36. Randell, E.W., Parkes, J.G., Olivieri, N.F. & Templeton, D.M. (1994) Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron. J. Biol. Chem. 269, 16046-16053.
37. Richardson, D.R. & Ponka, P. (1995) Identification of a mechanism of iron uptake by cells which is stimulated by hydroxyl radicals generated via the iron-catalysed Haber-Weiss reaction. Biochim. Biophys. Acta 1269, 105-114.
38. Agarwal, M.B., Gupte, S.S., Viswanathan, C., Vasandani, D., Ramanathan, J., Desai, N., Puniyani, R.R. & Chablani, A.T. (1992) Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br. J. Haematol. 82, 460-466.
39. Al-Refaie, F.N., Hershko, C., Hoffbrand, A.V., Kosaryan, M., Olivieri, N.F., Tondury, P. & Wonke, B. (1995) Results of long-term deferiprone (L1) therapy: a report by the International Study Group on oral iron chelators. Br. J. Haematol. 91, 224-229.
40. Pati, H.P. & Choudhury, V.P. (1999) Deferiprone (L1) associated neutropenia in beta thalassaemia major: an Indian experience. Eur. J. Haematol. 63, 267-268.
41. Tondury, P., Kontoghiorghes, G.J., Ridolfi-Luthy, A., Hirt, A., Hoffbrand, A.V., Lottenbach, A.M., Sonderegger, T. & Wagner, P. (1990) L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br. J. Haematol. 76, 550-553.
42. Richardson, D.R. (2001) The controversial role of deferiprone in the treatment of thalassemia. J. Laboratory Clin. Med. 137, 324-329.
43. Aydinok, Y., Nisli, G., Kavakli, K., Coker, C., Kantar, M. & Cetingul, N. (1999) Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey. Acta Haematol. 102, 17-21.
44. Diav-Citrin, O., Anatackovic, G. & Koren, G. (1999) An investigation into variability in the therapeutic response to deferiprone in patients with thalassaemia major. Ther. Drug Monit. 21, 74-81.
45. Taher, A., Chamoun, F.M., Koussa, S., Saad, M.A., Khoriaty, A.I., Neeman, R. & Mourad, F.H. (1999) Efficacy and side effects of deferiprone (L1) in thalassaerma patients not compliant with deferoxamine. Acta Haematol. 101, 173-177.
46. Wonke, B., Wright, C. & Hoffbrand, A.V. (1998) Combined therapy with deferiprone and desferrioxamine. Br. J. Haematol. 361-364.
47. Chenoufi, N., Drenou, B., Loreal, O., Pigeon, C., Brissot, P. & Lescoat, G. Antiproliferative effect of deferiprone on the Hep G2 cell line. Biochem. Pharmacol. 56, 431-437.
48. Cragg, L., Hebbel, R.P., Miller, W., Solovery, A., Selby, S. & Enright, H. (1998) The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. Blood 92, 632-638.